Treats keratoconus. Sold as Photrexa Viscous In Dextran 20%/Photrexa, Epioxa Hd/Epioxa. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Riboflavin 5'-Phosphate Sodium (sold as Photrexa Viscous In Dextran 20%/Photrexa, Epioxa Hd/Epioxa), first approved Jul 15, 2016, with 0 new uses approved and 0 published complete response letters.
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Riboflavin 5-phosphate Ophthalmic Solution | To Be Discontinued | Jan 20, 2026 | Jan 20, 2026 |
| B-Complex: A Nutraceutical SANS CountermeasureOptic Disc Edema, Endothelial Dysfunction · National Aeronautics and Space Administration (NASA) | Phase 1 | Recruiting | May 9, 2022 |
| A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus PatientsKeratoconus · Joseph B. Ciolino, MD | Not applicable | Not yet recruiting | Oct 12, 2020 |
| Jul 15, 2016 | Photrexa Viscous In Dextran 20%/Photrexa, Photrexa Viscous In Dextran 20%NDA 203324 · Efficacy (new indication or use) | Glaukos | 3 | Marketed |
| Oct 17, 2025 | Epioxa Hd/EpioxaNDA 219910 · New formulation or manufacturer | Glaukos | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA